Akebia Therapeutics
AKBA
#8851
Rank
A$0.32 B
Marketcap
A$1.19
Share price
1.80%
Change (1 day)
-72.62%
Change (1 year)

Earnings for Akebia Therapeutics (AKBA)

Earnings in 2026 (TTM): -A$40.72 Million

According to Akebia Therapeutics's latest financial reports the company's current earnings are A$0.21 Billion. In 2025 the company made an earning of -A$5.34 Million, an increase over its 2024 earnings that were of -A$99.52 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Akebia Therapeutics from 2013 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) -A$40.72 Million663.14%
2025 -A$5.34 Million-94.64%
2024 -A$99.52 Million33.68%
2023 -A$74.45 Million-45.12%
2022 -A$0.14 Billion-66.55%
2021 -A$0.41 Billion-26.24%
2020 -A$0.55 Billion33.94%
2019 -A$0.42 Billion66.52%
2018 -A$0.25 Billion123.53%
2017 -A$0.12 Billion-43.34%
2016 -A$0.2 Billion123.58%
2015 -A$87.05 Million63.95%
2014 -A$53.1 Million181.24%
2013 -A$18.88 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Johnson & Johnson
JNJ
A$37.57 B-94,217.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
A$22.25 B-55,842.30%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Amgen
AMGN
A$14.74 B-37,042.47%๐Ÿ‡บ๐Ÿ‡ธ USA
Nektar Therapeutics
NKTR
-A$0.22 Billion 449.86%๐Ÿ‡บ๐Ÿ‡ธ USA